SWEDEPAD 2: the debate is not over yet!
Just when you thought the discussion was over, the outcomes and implications of SWEDEPAD 2 make the debate around paclitaxel-coated devices continue.
On Tuesday, October 21, at 5:30 p.m. (CET), join Yann Gouëffic and Koen Deloose, PVI Course Directors, for a 30-minute live session in the PVI Studio.
They will be accompanied by Joakim Nordanstig (Principal Investigator, SWEDEPAD 2) and Eric Secemsky (Interventional cardiologist and researcher in device-based therapy for PAD).
Together, they’ll revisit this controversial trial, explore its results, clinical implications, remaining questions, and discuss its real-world application in vascular practice.
Don’t miss this opportunity to hear the insights of the trial’s authors and leading experts, and to engage with the ongoing discussion in a friendly, professional setting.
- If you already have an account, you can register for the webinar right away.
- If you don’t have one yet, you can create your free account in just a few clicks!
👉 Register now to join the debate!
📅 Live on Tuesday, October 21, 2025
🕠 17:30–18:00 (CET) | 11:30–12:00 (Boston time)
📍 PVI Studio – Online
Professor of Vascular Surgery
President of the association of the french university hospitals for clinical research
Conflicts of interest:
Research funding from Predisurge, Biotronik, WL Gore, GE Healthcare
Honoraria from Abbott, BD, Bentely, Biotronik, Boston Scientific, Cook, Eclevar Medtech, GE Healthcare, Ivascular, Medtronic, Penumbra, Sensome, Shockwave medical, WL Gore (consulting, medical advisory board, educational course, speaking)
Get the latest clinical cases and breaking news delivered straight to your inbox!
